Search Within

Ghassan Abou-Alfa

Formats
  1. Meeting Abstract (262)
  2. Journal Article (246)
  3. Review (27)
  4. Book Section (16)
  5. Editorial (8)
  6. Book Whole (4)
  7. Correspondence (4)
  8. Guidelines (4)
  9. Miscellaneous (3)
  10. Research Letter (1)
Groups
  1. Department of Medicine (575)
  2. Gastrointestinal Oncology Service (575)
  3. Solid Tumor Oncology Division (575)
  4. Center for Pancreatic Cancer Research (215)
  5. Epidemiology and Biostatistics (122)
  6. Surgery (103)

More Groups

People
  1. Eileen O'Reilly (156)
  2. James Harding (130)
  3. William Jarnagin (66)
  4. Marinela Capanu (65)
  5. Leonard Saltz (55)
  6. Imane El Dika (54)

More People

Years
  1. 2025 (20)
  2. 2024 (52)
  3. 2023 (48)
  4. 2022 (53)
  5. 2021 (46)
  6. 2020 (46)

More Years

Publications
  1. Journal of Clinical Oncology (166)
  2. Annals of Oncology (53)
  3. Gastrointestinal Cancer Research (21)
  4. Oncology Research and Treatment (18)
  5. Annals of Surgical Oncology (15)
  6. Cancer (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (182)
  2. Oxford University Press (65)
  3. Springer (36)
  4. Wiley Blackwell (30)
  5. Elsevier Inc. (25)
  6. Elsevier Science, Inc. (24)

More Publishers

Results (575)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma in the phase III CELESTIAL trial
    Meeting Abstract

    Strasser, S.; Abou-Alfa, G.; Meyer, T.; Cheng, A.; Cicin, I.; Bolondi, L.; Klumpen, H.; Chan, S.; Zagonel, V.; Milwee, S.; more...
    Journal of Gastroenterology and Hepatology (2019)

    Fulltext@MSK | Save
  • A phase Ib/II study of ramucirumab in combination with emibetuzumab in patients with advanced cancer
    Journal Article

    Harding, J. J.; Zhu, A. X.; Bauer, T. M.; Choueiri, T. K.; Drilon, A.; Voss, M. H.; Fuchs, C. S.; Abou-Alfa, G. K.; Wijayawardana, S. R.; Wang, X. A.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Gallbladder cancer, a forgotten global cancer problem
    Editorial

    Abou-Alfa, G. K.
    Chinese Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Evaluation and management of incidental gallbladder cancer
    Review

    Zaidi, M. Y.; Abou-Alfa, G. K.; Ethun, C. G.; Shrikhande, S. V.; Goel, M.; Nervi, B.; Primrose, J.; Valle, J. W.; Maithel, S. K.
    Chinese Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Biliary tract cancer prognostic and predictive genomics
    Review

    Mondaca, S.; Nervi, B.; Pinto, M.; Abou-Alfa, G. K.
    Chinese Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Systemic therapy for gallbladder cancer
    Review

    Javle, M.; Zhao, H.; Abou-Alfa, G. K.
    Chinese Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial
    Meeting Abstract

    Javle, M.; Borbath, I.; Clarke, S.; Hitre, E.; Louvet, C.; Macarulla, T.; Oh, D.; Spratlin, J.; Valle, J.; Weiss, K.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC)
    Meeting Abstract

    Miksad, R.; Cicin, I.; Chen, Y.; Klumpen, H.; Kim, S.; Lin, Z.; Youkstetter, J.; Sen, S.; Cheng, A.; Meyer, T.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: A phase 1 study
    Journal Article

    Lowery, M. A.; Burris, H. A. 3rd; Janku, F.; Shroff, R. T.; Cleary, J. M.; Azad, N. S.; Goyal, L.; Maher, E. A.; Gore, L.; Hollebecque, A.; more...
    The Lancet Gastroenterology & Hepatology (2019)

    Fulltext@MSK | Save
  • An open-label, multicenter, phase I, dose escalation study with phase II expansion cohort to determine the safety, pharmacokinetics, and preliminary antitumor activity of intravenous TKM-080301 in subjects with advanced hepatocellular carcinoma
    Journal Article

    El Dika, I.; Lim, H. Y.; Yong, W. P.; Lin, C. C.; Yoon, J. H.; Modiano, M.; Freilich, B.; Choi, H. J.; Chao, T. Y.; Kelley, R. K.; more...
    The Oncologist (2019)

    Fulltext@MSK | Save